SUPPLEMENTARY TABLE1: Changes in clinical status at day 28 in comparison to baseline assessed using the World Health Organization’s seven-category ordinal scale for clinical improvement.

	Total	Ixekizumab	Low-dose IL-2	Colchicine	Standard of care
	N= 60 (%)	N = 16 (%)	N = 14 (%)	N = 14 (%)	N = 16 (%)
3	4 (6.7)	0 (0.0)	2 (14.3)	0 (0.0)	2 (12.5)
2	2 (3.3)	2 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)
1	1 (1.7)	1 (6,3)	0 (0.0)	0 (0.0)	0 (0.0)
0	2 (3.3)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)
-1	2 (3.3)	0 (0.0)	1 (7.1)	0 (0.0)	1 (6.3)
-2	6 (10.0)	2 (12.5)	1 (7.1)	2 (14.3)	1 (6.3)
-3	24 (40.0)	5 (31.3)	5 (35.7)	6 (42.9)	8 (50.0)
-4	15 (25.0)	5 (31.3)	1 (7.1)	6 (42.9)	3 (18.8)
-5	4 (6.7)	1 (6.3)	2 (14.3)	0 (0.0)	1 (6.3)

Data are presented as n (%) or n (%). WHO Ordinal Scale: World Health Organization Ordinal Scale for Clinical Improvement, respectively. Delta was calculated as the score assessed on day 28 minus the score assessed on day 1. Negative values indicate clinical improvement.